Concurrent inhibition of angiogenesis and immune checkpoints represents a potent therapeutic approach.We conducted a phase 2,multicenter,basket study to assess the efficacy and safety of combination therapy of famitin...Concurrent inhibition of angiogenesis and immune checkpoints represents a potent therapeutic approach.We conducted a phase 2,multicenter,basket study to assess the efficacy and safety of combination therapy of famitinib(anti-angiogenic agent)plus camrelizumab(PD-1 antagonist)in patients with metastatic solid tumors across 11 cohorts(this study was registered at Clinicaltrials.gov[NCT04346381]).This report focuses on the cohort of patients with metastatic or advanced colorectal cancer.Eligible patients,who had previously received R2 lines of systemic treatments for their metastatic disease,were treated with famitinib(20 mg once daily)in combination with camrelizumab(200 mg intravenously every 3 weeks).The primary endpoint was the objective response rate,with secondary endpoints encompassing progressionfree survival,overall survival,duration of response,safety and exploratory biomarkers.A total of 44 patients were enrolled and treated.With a median follow-up time of 9.46 months(range 2.0-22.5 months),objective responses were observed in 6 patients(13.6%;95%confidence interval[CI],5.2%-27.4%),all of whom had rectal cancer.The median duration of response is 6.2 months(95%CI,2.3-10.6 months).Median progression-free survival was 3.3 months(95%CI,2.1-4.1 months),and median overall survival was 10.9 months(95%CI,7.6-15.2 months).Among the 44 patients,29(65.9%)experienced grade 3 or 4 treatment-related adverse events,predominantly hypertension and proteinuria.In conclusion,the combination of famitinib and camrelizumab demonstrates promising antitumor activity with a manageable safety profile in metastatic colorectal cancer patients.Further research is warranted to confirm and extend these findings.展开更多
基金supported by Jiangsu Hengrui Pharmaceuticals Co.,Ltd.,National Natural Science Foundation of China(82373402,82272775)Shanghai Shen-kang Hospital Development Center(SHDC2022CRT001)+1 种基金Shanghai Rising-Star Program(21QA1401600)the Cancer Center,Zhongshan Hospital(2023XKPT19-RC1).
文摘Concurrent inhibition of angiogenesis and immune checkpoints represents a potent therapeutic approach.We conducted a phase 2,multicenter,basket study to assess the efficacy and safety of combination therapy of famitinib(anti-angiogenic agent)plus camrelizumab(PD-1 antagonist)in patients with metastatic solid tumors across 11 cohorts(this study was registered at Clinicaltrials.gov[NCT04346381]).This report focuses on the cohort of patients with metastatic or advanced colorectal cancer.Eligible patients,who had previously received R2 lines of systemic treatments for their metastatic disease,were treated with famitinib(20 mg once daily)in combination with camrelizumab(200 mg intravenously every 3 weeks).The primary endpoint was the objective response rate,with secondary endpoints encompassing progressionfree survival,overall survival,duration of response,safety and exploratory biomarkers.A total of 44 patients were enrolled and treated.With a median follow-up time of 9.46 months(range 2.0-22.5 months),objective responses were observed in 6 patients(13.6%;95%confidence interval[CI],5.2%-27.4%),all of whom had rectal cancer.The median duration of response is 6.2 months(95%CI,2.3-10.6 months).Median progression-free survival was 3.3 months(95%CI,2.1-4.1 months),and median overall survival was 10.9 months(95%CI,7.6-15.2 months).Among the 44 patients,29(65.9%)experienced grade 3 or 4 treatment-related adverse events,predominantly hypertension and proteinuria.In conclusion,the combination of famitinib and camrelizumab demonstrates promising antitumor activity with a manageable safety profile in metastatic colorectal cancer patients.Further research is warranted to confirm and extend these findings.
